The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

The dulaglutide market has seen strong growth in recent years, driven by increasing demand for diabetes management solutions. This blog explores the current trends, future forecasts, and the key factors propelling the market forward.

Dulaglutide Market Growth Overview

• The dulaglutide market grew from $3.87 billion in 2023 to $4.17 billion in 2024, marking a compound annual growth rate (CAGR) of 7.7%.
• The growth has been attributed to the rising prevalence of type 2 diabetes, increased utilization of dulaglutide, growing investments in research and development, and a heightened focus on chronic diseases.
• The expansion of personalized medicine has also contributed significantly to the market’s growth.

Future Market Growth Forecast

• The dulaglutide market is expected to reach $5.66 billion by 2028, with a CAGR of 7.9%.
• Key drivers of this growth include rising rates of obesity, an aging population, increasing clinical trials, and the expansion of telemedicine services.
• Other contributing factors are the rise in endocrinology clinics and the increased use of electronic health records (EHRs) for better diabetes management.

View More On The Dulaglutide Market Report 2024 – https://www.thebusinessresearchcompany.com/report/dulaglutide-global-market-report

Key Market Driver: Rising Prevalence of Type 2 Diabetes

• The increasing prevalence of type 2 diabetes is a major factor driving the growth of the dulaglutide market.
• Type 2 diabetes, a chronic condition characterized by insulin resistance or inadequate insulin production, has been on the rise due to unhealthy diets, sedentary lifestyles, and growing obesity rates.
• Dulaglutide helps manage the condition by enhancing insulin secretion and reducing glucagon levels, effectively lowering blood sugar.
• According to the International Diabetes Federation, the number of people affected by diabetes is expected to rise from 537 million in 2021 to 783 million by 2045, which will drive continued demand for treatments like dulaglutide.

Global Dulaglutide Market Major Players

• Major companies in the dulaglutide market include Merck & Co. Inc., AstraZeneca PLC, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, and Cipla Limited.
• Other key players include Intas Pharmaceuticals, Biocon Limited, Glenmark Pharmaceuticals, Insulet Corporation, and MannKind Corporation.
• These companies are constantly innovating and expanding their product portfolios to meet the growing demand for diabetes management solutions.

Market Trend: Biosimilars Expanding Access to Anti-Diabetic Drugs

• Biosimilars are playing a crucial role in expanding access to anti-diabetic treatments, particularly in developing countries.
• In January 2024, Glenmark Pharmaceuticals launched Lirafit, a biosimilar of the anti-diabetic drug Liraglutide, in India. This move reflects the company’s strategic entry into the biosimilar market, aiming to provide more affordable treatment options for patients with type 2 diabetes.
• Such biosimilar drugs are expected to offer the same efficacy and safety as the original medications, making diabetes management more accessible.

Merger and Acquisition: Lupin Strengthens Diabetes Portfolio

• Mergers and acquisitions are a growing trend in the dulaglutide market, helping companies strengthen their market presence.
• In August 2023, Lupin Limited acquired two diabetic brands from Boehringer Ingelheim for €26 million ($28 million). This acquisition enhances Lupin’s diabetes care portfolio, helping the company offer a more comprehensive range of products for managing type 2 diabetes.
• This strategic move highlights the growing competition in the diabetes treatment market, with companies expanding their portfolios through acquisitions to capture a larger market share.

Market Segmentation

• The dulaglutide market is segmented by type, including syringe pens and multi-dose bottles.
• It is also divided by application, with categories like medical insurance, pharmaceuticals, and clinical research.
• Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, offering diverse access points for patients and healthcare providers.

Regional Outlook for the Global Dulaglutide Market

• North America led the dulaglutide market in 2023, driven by high diabetes prevalence, advanced healthcare infrastructure, and strong pharmaceutical research and development.
• However, regions such as Asia-Pacific and Europe are expected to experience significant growth in the coming years due to rising healthcare access, growing awareness of diabetes management, and expanding telemedicine services.

Request A Sample Of The Global Dulaglutide Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=18338&type=smp